Treatment of Waldenstrom's macroglobulinemia with rituximab: prognostic factors for response and progression.

abstract：:The relationship between histopathologic characteristics and treatment outcomes in patients with diffuse large B-cell lymphoma (DLBCL) treated with rituximab-based immunochemotherapy needs re-evaluation. Patients with newly diagnosed DLBCL treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednis...

journal_title：Leukemia & lymphoma

authors： Hong J,Park S,Park J,Kim HS,Kim KH,Ahn JY,Rim MY,Jung M,Sym SJ,Cho EK,Shin DB,Lee JH

更新日期：2011-10-01 00:00:00

abstract：:Following the introduction of the WHO classification of chronic myeloproliferative disorders (MPDs), after approximately 5 years, a critical reappraisal appears to be warranted. Retrospective clinico-pathological evaluations conducted in the meantime, as well as the detection of new biomarkers, may aid in testing the ...

journal_title：Leukemia & lymphoma

authors： Thiele J,Kvasnicka HM

更新日期：2006-03-01 00:00:00

abstract：:Interleukin-4 (IL-4), also known as B-cell stimulatory factor-1 (BSF-1), was initially identified as a T-cell product that mediates anti-IgM-induced DNA synthesis in B-lymphocytes. Various aspects of this highly pleiotropic cytokine have been described, including those on hematopoietic progenitor cells. However, the r...

journal_title：Leukemia & lymphoma

authors： Sawada K,Sato N,Koike T

更新日期：1995-09-01 00:00:00

abstract：:This study was designed to investigate the immunostimulatory effect of low dose Il-2 treatment in B-CLL patients previously treated with 2-chlorodeoxyadenosine (2CdA) in whom severe depletion of T lymphocyte subsets was observed. Four patients enrolled into the study had previously been treated with 3-6 courses of 2Cd...

journal_title：Leukemia & lymphoma

authors： Dmoszyńska A,Legiec W,Wach M

更新日期：1999-07-01 00:00:00

abstract：:Anti-B4-blocked ricin (anti-B4-bR) is a potent immunotoxin directed against the CD19 antigen. Previous phase I and II studies suggested a possible role for anti-B4-bR as consolidation after high-dose chemotherapy and autologous stem cell transplant. Cancer and Leukemia Group B (CALGB) 9254 is a phase III study which r...

journal_title：Leukemia & lymphoma

authors： Furman RR,Grossbard ML,Johnson JL,Pecora AL,Cassileth PA,Jung SH,Peterson BA,Nadler LM,Freedman A,Bayer RL,Bartlett NL,Hurd DD,Cheson BD,Cancer Leukemia Group B.,Eastern Cooperative Oncology Group.

更新日期：2011-04-01 00:00:00

abstract：:The combination of chromosomal translocations associated with bcl-2 rearrangement [t(14;18)] and c-myc rearrangement [t(8;14), t(8;22), or t(2;8)] has infrequently been detected in lymphoproliferative disorders. We have recently identified four cases of a B-cell malignancy exhibiting this dual translocation. In additi...

journal_title：Leukemia & lymphoma

authors： Karsan A,Gascoyne RD,Coupland RW,Shepherd JD,Phillips GL,Horsman DE

更新日期：1993-08-01 00:00:00

abstract：:The percentage of blasts in the bone marrow aspirates at day 7 or 14 of induction therapy in pediatric ALL patients is an indicator of rapid early response and an independent prognostic factor for long term outcome. Discrepancies between the percentages of blasts in bone marrow aspirates compared to biopsies have been...

journal_title：Leukemia & lymphoma

authors： Countouriotis A,Landaw EM,Naeim F,Moore TB,Sakamoto KM

更新日期：2004-04-01 00:00:00

abstract：:To define the specific genetic alterations in nasal natural killer/T-cell lymphoma (N-NK/T-L), the assay of restriction landmark genomic scanning (RLGS), a genome-wide method, was used to investigate a pair of genomic DNA from N-NK/T-L cells and peripheral blood leukocytes of the same patient. The intensified spots in...

journal_title：Leukemia & lymphoma

authors： Ye Y,Li T,Zhang B,Guo Z

更新日期：2007-01-01 00:00:00

abstract：:Plasmablastic lymphoma (PBL) is a recently described type of non-Hodgkin's lymphoma (NHL) that occurs in up to 3% of patients with HIV infection. Although the clinical-pathological features of several patients with HIV-associated plasmablastic lymphoma are documented, detailed description of clinical outcome is limite...

journal_title：Leukemia & lymphoma

authors： Lester R,Li C,Phillips P,Shenkier TN,Gascoyne RD,Galbraith PF,Vickars LM,Leitch HA

更新日期：2004-09-01 00:00:00

abstract：:The proteasome inhibitor carfilzomib is highly effective in the treatment of multiple myeloma. It irreversibly binds the chymotrypsin-like active site in the β5 subunit of the 20S proteasome. Despite impressive response rates when carfilzomib is used in combination with immunomodulatory agents in newly diagnosed multi...

journal_title：Leukemia & lymphoma

authors： Manasanch EE,de Larrea CF,Zingone A,Steinberg SM,Kwok M,Tageja N,Bhutani M,Kazandjian D,Roschewski M,Wu P,Carter G,Zuchlinski D,Mulquin M,Lamping L,Costello R,Burton D,Gil LA,Figg WD,Maric I,Calvo KR,Yuan C,Stet

更新日期：2017-03-01 00:00:00

abstract：:Eighteen patients (pts) with myelodysplastic syndrome (MDS) were treated with thymopentin (TP) (50 mg subcutaneously for 5 days) and recombinant interferon alpha 2a (rIFN alpha 2a) (3 MU/m2 subcutaneously on the sixth day); the courses were delivered every week. Moreover those pts with > or = 10% blasts in the bone ma...

journal_title：Leukemia & lymphoma

authors： Venditti A,Scimò MT,del Poeta G,Buccisano F,Stasi R,Mastino A,Grelli S,Favalli C,Garaci E,Papa G

更新日期：1995-01-01 00:00:00

abstract：:Patients with multiple myeloma who are refractory or intolerant to both bortezomib and lenalidomide have a poor prognosis. Next-generation therapies carfilzomib and pomalidomide have shown promising activity in this dual refractory population. Here we describe the clinical characteristics and ascertain the effects of ...

journal_title：Leukemia & lymphoma

authors： Wang TF,Ahluwalia R,Fiala MA,Trinkaus KM,Cox DP,Jaenicke M,Moliske CC,Carson KR,Wildes TM,Tomasson MH,Stockerl-Goldstein KE,Vij R

更新日期：2014-02-01 00:00:00

abstract：:We attempted to analyze whether the use of high-dose cyclophosphamide (CTX 7g/m2, group A) plus hematopoietic growth factor (G-CSF) or G-CSF alone (10 microg/Kg, group B) as a mobilizing regimen, could result in harvesting different numbers of CD34+ cells, committed progenitors and CD34+ cells subsets. The number of C...

journal_title：Leukemia & lymphoma

authors： Dazzi C,Cariello A,Rosti G,Argnani M,Sebastiani L,Ferrari E,Zornetta L,Monti G,Nicoletti P,Baioni M,Salvucci M,Scarpi E,Marangolo M

更新日期：2000-10-01 00:00:00

abstract：:Chromosome aberrations affecting 3q27 are among the most frequent non-random abnormalities in non-Hodgkin's lymphomas (NHL), especially the diffuse, large cell type. Recently, an association between BCL6 rearrangement and frequent extranodal lesions, rare bone marrow infiltration and a favorable clinical outcome was r...

journal_title：Leukemia & lymphoma

authors： Ohshima A,Miura I,Hashimoto K,Takahashi N,Utsumi S,Nimura T,Saito M,Miki T,Hirosawa S,Miura AB

更新日期：1997-10-01 00:00:00

abstract：:Nucleoside analogs are important components of treatment regimens for acute leukemia in adults. Plasma membrane permeation of the nucleoside analog molecules, the initial event in the cellular conversion of nucleosides to active agents, is mediated by nucleoside-specific membrane transporters. The widely-expressed es ...

journal_title：Leukemia & lymphoma

authors： Gati WP,Paterson AR,Belch AR,Chlumecky V,Larratt LM,Mant MJ,Turner AR

更新日期：1998-12-01 00:00:00

abstract：:Ibrutinib and idelalisib are kinase inhibitors that have revolutionized the treatment of chronic lymphocytic leukemia (CLL). Capable of inducing durable remissions, these agents also modulate the immune system. Both ibrutinib and idelalisib abrogate the tumor-supporting microenvironment by disrupting cell-cell interac...

journal_title：Leukemia & lymphoma

authors： Pleyer C,Wiestner A,Sun C

更新日期：2018-12-01 00:00:00

abstract：:Deletion of chromosome 6q has frequently been observed in natural killer (NK) cell lymphomas. The aim of this study, is to localize the commonly affected region in chromosome 6q and to compare the frequency of loss of heterozygosity (LOH) between the peripheral T and NK cell lymphomas. Eight cases of peripheral T cell...

journal_title：Leukemia & lymphoma

authors： Yoon J,Ko YH

更新日期：2003-12-01 00:00:00

abstract：:Multiple myeloma typically presents with monoclonal proteinemia, marrow plasmacytosis, anemia, bony involvement, hypercalcemia and renal insufficiency. Less frequent presentations include hepatic and splenic enlargement (5% of cases), lymphadenopathy (4%) and biclonal gammopathy (1%). Chemotherapy may produce remissio...

journal_title：Leukemia & lymphoma

authors： Daeninck PJ,Williams GJ,Rubinger M,Johnston JB

更新日期：1997-12-01 00:00:00

abstract：:The human analogue of the mouse double minute-2 (MDM-2) protein binds to p53 protein and abrogates its tumor-suppressing activity. MDM-2 overexpression may represent an alternative mechanism to p53 mutation for escaping the p53-mediated growth control. Interestingly, multiple MDM-2 protein isoforms have been described...

journal_title：Leukemia & lymphoma

authors： Bueso-Ramos CE,Manshouri T,Haidar MA,Huh YO,Keating MJ,Albitar M

更新日期：1995-03-01 00:00:00

abstract：:Recent data have elucidated the pathogenesis of transient abnormal myelopoiesis (TAM) to a great extent. TAM is a monoclonal disorder which resolves spontaneously and the target cell in this disorder is a multipotent stem cell which is capable of differentiating into megakaryocytes. The pathogeneses of TAM/AMKL (acute...

journal_title：Leukemia & lymphoma

authors： Kurahashi H,Hara J,Yumura-Yagi K,Tawa A,Kawa-Ha K

更新日期：1992-12-01 00:00:00

abstract：:Recombinant interleukin-21 (IL-21) has potential utility in cancer therapy. Stimulation with IL-21 can induce apoptosis in follicular lymphoma (FL) cells, and existing studies have suggested that IL-21 signaling may function in tumor suppression. In order to elucidate the relationship between IL-21 receptor (IL-21R) e...

journal_title：Leukemia & lymphoma

authors： Wood B,Sikdar S,Choi SJ,Virk S,Alhejaily A,Baetz T,LeBrun DP

更新日期：2013-06-01 00:00:00

abstract：:Abstract Acute graft-versus-host disease (GVHD) has compromised and continues to compromise the benefits associated with allogeneic hematopoietic cell transplant to cure malignant and non-malignant diseases. Pharmacologic interventions to prevent GVHD have emerged as a major objective of research in the immunology and...

journal_title：Leukemia & lymphoma

authors： Ram R,Storb R

更新日期：2013-08-01 00:00:00

abstract：:Gallium (67Ga) scan was performed in 29 CLL patients with chronic lymphocytic leukemia who were suspected on clinical grounds to have Richter's transformation (RT). Of 29 patients, nine had a positive 67Ga scan; seven of these had a subsequent biopsy that verified large-cell lymphoma or Hodgkin's disease. The other tw...

journal_title：Leukemia & lymphoma

authors： Partyka S,O'Brien S,Podoloff D,Kantarjian H,Keating MJ

更新日期：1999-12-01 00:00:00

abstract：:In developed nations, Hodgkin lymphoma (HL) is rare in <5-year olds and represent a minority in developing countries. Little is reported about the biology and behavior of these very young patients compared with older children. 18.75% of our pediatric HL patients (0 - 14 years) were <5 years at diagnosis. This group ha...

journal_title：Leukemia & lymphoma

authors： Belgaumi A,Al-Kofide A,Joseph N,Jamil-Malik R,Khafaga Y,Sabbah R

更新日期：2008-05-01 00:00:00

abstract：:Fludarabine (FLUDA) based chemotherapy has shown promise in both initial and salvage treatment of low-grade non Hodgkin's lymphomas (LG-NHL). Recently, more aggressive therapies followed by autologous hemopoietic progenitor cell rescue, have also been successfully employed in these patients. However, this procedure, d...

journal_title：Leukemia & lymphoma

authors： Laszlo D,Galieni P,Raspadori D,Scalia G,Bigazzi C,Bocchia M,Bucalossi A,Marotta G,Tozzi M,Lauria F

更新日期：2000-03-01 00:00:00

abstract：:The epidemiology of splenic marginal zone lymphoma (SMZL) in the United States has not been addressed. Eight years of data (2001-2008) from 17 registries of the Surveillance, Epidemiology and End Results (SEER) program were used for this study. Of the 116,411 cases of non-Hodgkin lymphoma (NHL) in the registries, 763 ...

journal_title：Leukemia & lymphoma

authors： Liu L,Wang H,Chen Y,Rustveld L,Liu G,Du XL

更新日期：2013-07-01 00:00:00

abstract：:Recent measures to classify novel molecular targets with therapeutic potential across multiple hematologic tumors have identified the eukaryotic nuclear exporter, exportin 1 (XPO1), as a promising candidate. Molecular agents termed 'Selective Inhibitors of Nuclear Export' (SINEs) have been developed to selectively inh...

journal_title：Leukemia & lymphoma

authors： Walker JS,Garzon R,Lapalombella R

更新日期：2020-10-01 00:00:00

abstract：:We present a female patient with monoclonal gammopathy of undetermined significance who has remained stable for five years but evolved to overt myeloma in strict temporal relationship with the diagnosis of GH-secreting pituitary macroadenoma. IGF-I serum levels correlated with serum and urine M component. Since the in...

journal_title：Leukemia & lymphoma

authors： Tucci A,Bonadonna S,Cattaneo C,Ungari M,Giustina A,Guiseppe R

更新日期：2003-03-01 00:00:00

abstract：:Primary central nervous system (PCNS) lymphoma is a relatively rare disease. The Epstein-Barr virus (EBV) has often been implicated in the development of lymphomas. Few cytogenetic. studies on PCNS lymphomas have been reported. We describe here an unusual case of PCNS B cell lymphoma, centroblastic polymorphic type wi...

journal_title：Leukemia & lymphoma

authors： Zattara-Cannoni H,Horshowski N,Figarella-Branger D,Dufour H,Grisoli F,Vagner-Capodano AM

更新日期：1996-05-01 00:00:00

abstract：:The increased number of CD5+ B-cells in some human autoimmune diseases, the frequent commitment of CD5+ B-cells to the production of natural autoantibodies, and the apparent involvement of these cells in the pathogenesis of the autoimmune hemolytic anemia (AIHA) in certain mouse models suggests a causal relationship b...

journal_title：Leukemia & lymphoma

authors： Efremov DG,Ivanovski M,Burrone OR

更新日期：1998-01-01 00:00:00